Another evidence supporting the idea that SIRT-3 activation could be a good approach in neurodegenerative disorders is that Honokiol, a not specific SIRT-3 activator, decreases ROS and lipid peroxidation, enhances antioxidant activities, and mitochondrial function, thereby reducing β-amyloid and sAPPβ production in an AD model. This evidence concerns the gene SIRT3 and Alzheimer disease.